Literature DB >> 10657678

Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain.

T Samandari1, K L Kotloff, G A Losonsky, W D Picking, P J Sansonetti, M M Levine, M B Sztein.   

Abstract

Volunteers were orally administered invasive, non-Shiga toxin-producing Shigella dysenteriae 1 to establish a challenge model to assess vaccine efficacy. In stepwise fashion, four separate groups were given 3 x 10(2), 7 x 10(3), 5 x 10(4), or 7 x 10(5) CFU. Using PBMC, proliferative responses and cytokine production were measured to S. dysenteriae whole-cell preparations and to purified recombinant invasion plasmid Ags (Ipa) C and IpaD. Anti-LPS and anti-Ipa Abs and Ab-secreting cells were also evaluated. Preinoculation PBMC produced considerable quantities of IL-10 and IFN-gamma, probably secreted by monocytes and NK cells, respectively, of the innate immune system. Following inoculation, PBMC from 95 and 87% of volunteers exhibited an increased production of IFN-gamma and IL-10, respectively, in response to Shigella Ags. These increases included responses to IpaC and IpaD among those volunteers receiving the lowest inoculum. No IL-4 or IL-5 responses were detected. Whereas there were no Ab or Ab-secreting cell responses in volunteers receiving the lowest inoculum, other dose groups had moderate to strong anti-LPS and anti-Ipa responses. These results suggest that in humans, type 1 responses play an important role in mucosal and systemic immunity to S. dysentariae 1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657678     DOI: 10.4049/jimmunol.164.4.2221

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.

Authors:  Rezwanul Wahid; Rosangela Salerno-Gonçalves; Carol O Tacket; Myron M Levine; Marcelo B Sztein
Journal:  Vaccine       Date:  2006-11-03       Impact factor: 3.641

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 4.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Authors:  K L Kotloff; F R Noriega; T Samandari; M B Sztein; G A Losonsky; J P Nataro; W D Picking; E M Barry; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

6.  Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

Authors:  J K Simon; M Maciel; E D Weld; R Wahid; M F Pasetti; W L Picking; K L Kotloff; M M Levine; M B Sztein
Journal:  Clin Immunol       Date:  2011-03-08       Impact factor: 3.969

7.  Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Authors:  K R Turbyfill; A B Hartman; E V Oaks
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

8.  Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Authors:  Karen L Kotloff; David N Taylor; Marcelo B Sztein; Steven S Wasserman; Genevieve A Losonsky; James P Nataro; Malabi Venkatesan; Antoinette Hartman; William D Picking; David E Katz; James D Campbell; Myron M Levine; Thomas L Hale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.

Authors:  Rezwanul Wahid; Jakub K Simon; Wendy L Picking; Karen L Kotloff; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2013-03-26       Impact factor: 3.969

10.  Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.

Authors:  J K Simon; R Wahid; M Maciel; W L Picking; K L Kotloff; M M Levine; M B Sztein
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.